U.S. Serial No. 10/621,909
Attorney Docket No. QA0266 NP

REMARKS

Status of the Claims

Claims 13 and 18-20 are canceled.

Claims 1-12, 14-17 and 21-34 are allowed.

Amendment

In the proviso of claim 1 under part I., subpart (3) has been deleted as this section of the proviso was rendered moot by the restriction requirement (mailed May 21, 2004) that required one of R^1 or R^2 to be heteroaryl.

Additionally, claims 1, 2, 6, 8, 9, 10-12, 15, 17, and 24-27 have been amended to correct improper alternative claim language.

None of the aforementioned amendments add new material or broaden the scope of the claims.

Examiner's Amendment

The Examiner contacted Applicants by telephone on November 10, 2004 and indicated that Claims 1-12, 14-17 and 21-34 (renumbered as claims 1-30) were allowable if the method claims 18 and 20 were canceled and the phrase ", or a prodrug ester thereof" were removed from the claims. Applicants disagree with the Examiner's contention that the ", or a prodrug ester thereof" phrase rendered the claims indefinite for the reasons stated in the amendment dated September 10, 2004. However, in order to expedite prosecution of this application, the undersigned authorized the Examiner's Amendment (as detailed in the Notice of Allowance mailed November 17, 2004) and . reserves the right to pursue unclaimed subject matter in one or more divisional applications.

FEES

No fees should be due. However, if it is determined that a fee is due, please charge same to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

U.S. Serial No. 10/621,909
Attorney Docket No. QA0266 NP

SUMMARY

In view of the foregoing, it is requested that this case proceed to issuance. The Examiner is invited to contact the undersigned if it is believed prosecution could be expedited.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-5323

Laurelee A. Duncan
Attorney for Applicants
Reg. No. 44,096

Date: February 16, 2005